43,621 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Purchased by Twinbeech Capital LP

Twinbeech Capital LP acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 43,621 shares of the medical research company’s stock, valued at approximately $22,693,000.

Several other institutional investors also recently bought and sold shares of the company. Stonegate Investment Group LLC grew its position in Thermo Fisher Scientific by 0.3% in the 4th quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company’s stock valued at $3,531,000 after acquiring an additional 18 shares in the last quarter. Semus Wealth Partners LLC lifted its stake in Thermo Fisher Scientific by 4.0% during the fourth quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company’s stock worth $245,000 after purchasing an additional 18 shares during the last quarter. Evernest Financial Advisors LLC lifted its stake in Thermo Fisher Scientific by 4.0% in the fourth quarter. Evernest Financial Advisors LLC now owns 521 shares of the medical research company’s stock valued at $271,000 after buying an additional 20 shares during the last quarter. Proactive Wealth Strategies LLC lifted its stake in Thermo Fisher Scientific by 2.7% in the fourth quarter. Proactive Wealth Strategies LLC now owns 753 shares of the medical research company’s stock valued at $392,000 after buying an additional 20 shares during the last quarter. Finally, Cassaday & Co Wealth Management LLC lifted its stake in Thermo Fisher Scientific by 0.9% in the fourth quarter. Cassaday & Co Wealth Management LLC now owns 2,286 shares of the medical research company’s stock valued at $1,189,000 after buying an additional 20 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now directly owns 115,174 shares in the company, valued at approximately $59,506,950.58. This trade represents a 7.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,075 shares of company stock valued at $7,305,942 in the last ninety days. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Argus dropped their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Citigroup lowered their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Stifel Nicolaus lowered their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. UBS Group reduced their target price on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. Finally, Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, April 24th. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $607.43.

Thermo Fisher Scientific Trading Up 1.8%

NYSE TMO opened at $412.15 on Monday. The firm has a market capitalization of $155.58 billion, a price-to-earnings ratio of 24.93, a PEG ratio of 2.99 and a beta of 0.82. The company’s 50 day moving average price is $453.88 and its 200 day moving average price is $509.89. Thermo Fisher Scientific Inc. has a one year low of $390.50 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business’s revenue was up .2% on a year-over-year basis. During the same period last year, the business earned $5.11 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were issued a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.42%. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.